For marketing purposes Swiss edition Data as at end-April 2022 ISIN: LU0577510026


UBS Equity Greater China

Performance Review

UBS (Lux) Equity Fund - Greater China (USD) (EUR) N-acc



Performance (basis EUR, net of fees)¹



Fund performance per year in % net of fees (right-hand scale)

..... Index performance (left-hand scale)

Past performance is not a reliable indicator of future results.

Performance in % (net of fees)¹

in %	2018	2019	2020	2021	2022 YTD ²	Apr. 2022	5 years	Ø p.a. 5 years
Fund (EUR)	-9.97	43.48	21.22	-14.09	-10.34	-0.78	43.88	7.55
Ref. Index ³	-11.91	25.75	15.23	-1.57	-8.65	-0.63	28.96	5.22
The performance shown does not take account of any commissions, entry or exit								

charges.

These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.
YTD: year-to-date (since beginning of the year)

3 Reference Index in currency of share class (without costs)

The Greater China markets continued to see a decline in performance in April on the back of a confluence of global (geopolitical tensions, American depository receipt delisting) and domestic factors (Covid outbreak and lockdowns, property downturn, regulatory pressures and uninspiring Q1 results).

Monthly performance

In April the fund performed negatively with 0.8%. However, the funds lost less than the overall region. Greater China equities extended their weakness on various negative market drivers.

YTD performance

YTD as of the end of April, the fund has delivered a negative performance of 10.3%. The strategy is down in the year to date amidst the overall market weakness despite strong stock selection in real estate and healthcare. Stock selection in financials was a drag on performance.

Performance contributors

Over the month, positions in communication services and consumer staples added the most value. NetEase was the key stock contributor over the month, and this has also been the case in the year to date. The resumption of gaming licence approvals served as a positive stimulus to the sector.

Performance detractors

Stock selection in financials was negative. China Merchants Bank, which is a key holding, fell on Tian Huiyu stepping down as president and director of the bank. We do not think the management change will have a material impact on CMB's financials.

Internet: www.ubs.com/funds Contact your client advisor Portfolio management representatives Bin Shi Morris Wu Denise Cheung

UBS Fund Infoline: 0800 899 899

For more information

UBS Equity Greater China

Market exposure (%)

Fund
80.7
8.7
6.6
3.9

Sector exposure (%)

	Fund
Financial Services	22.5
Communication Services	19.7
Consumer Staples	14.8
Information Technology	10.4
Consumer Discretionary	9.3
Real estate	7.3
Health Care	6.5
Cash	3.9
Industrials	3.6
Materials	1.4
Utility	0.5
Others	0.0

10 largest equity positions (%)

	Fund
KWEICHOW MOUTAI CO LTD A	9.63
TENCENT HOLDINGS LTD	9.59
TAIWAN SEMICONDUCTOR TWD10	8.72
NETEASE INC	7.79
PING AN INSURANCE 'H' CNY1	4.61
HONG KONG EXCHANGES & CLEAR HKD1	4.60
CHINA MERCHANTS BANK CNY1	4.27
ALIBABA GROUP HOLDING LTD	4.13
CSPC PHARMACEUTICAL GROUP LT	3.94
PING AN BANK CO LTD A	3.86

Current investment strategy

Over the past two months, the government has pledged more policy support to stabilise the economy and the market. We are seeing monetary, fiscal and credit easing from policymakers to boost growth. Overall, we have become more positive with regard to Chinese equities in 2022. We are optimistic about investing actively in the Chinese equity market for the long run.

Risks

UBS Emerging Market Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate from that of its reference index. Investors should also be aware of the political and social challenges that emerging markets face. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/ funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.